Additionally, there is a lack of data in certain subgroups (e.g., elderly patients, those with comorbidities like inflammatory bowel disease, or severe forms of PsA), highlighting the need for subgroup analyses to assess the efficacy and safety of IL-23 inhibitors in these populations. This evidence concerns the gene IL37 and inflammatory bowel disease.